Background: Alzheimer's Disease Neuroimaging Initiatives ("ADNI") aim to validate neuroimaging and biochemical markers of Alzheimer's disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported. Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We measured CSF β-amyloid 42 (CSF Aβ42), total tau-protein (t-tau), phosphorylated tau-proteins (P-tau181, P-tau231), plasma β-amyloid 40 and 42 (Aβ40/Aβ42). Immediate fresh shipment was compared to freezing and later shipment on dry ice. Results: CSF T-tau (fresh samples) was increased in AD versus controls (p = 0.049), CSF Aβ42 (frozen samples) was decreased in MCI and AD (p = 0.02), as well as plasma Aβ40 (fresh and frozen samples) in AD (p = 0.049 and p = 0.016). Pooled values of neurochemical parameters and ratios thereof were different between centres (p <0.005). Analysis of frozen samples yielded higher diagnostic accuracy than immediate fresh shipment with 100% (fresh: 100%) correctly classified in control subjects, 100% (78%) in MCI, 91% (91%) in AD. Conclusion: The use of frozen rather than fresh samples renders higher diagnostic accuracy within a multicentre context. We confirmed the feasibility of a multicentre AD biomarker programme for future clinical trials.
- Alzheimer's disease (AD)
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Biological marker
- Mild cognitive impairment (MCI)
ASJC Scopus subject areas
- Cell Biology
- Molecular Biology